膀胱内注射肉毒杆菌毒素治疗下尿路功能障碍。
Intravesical botulinum toxin for lower urinary tract dysfunction.
作者信息
John Drake Marcus
机构信息
Bristol Urological Institute Southmead Hospital, Bristol, BS10 5NB UK.
出版信息
F1000 Med Rep. 2010 Jan 27;2:6. doi: 10.3410/M2-6.
Abstract
Botulinum neurotoxin has achieved substantial clinical benefits in neurogenic detrusor overactivity. More contentious has been its extension to management of refractory idiopathic detrusor overactivity, in which risk of impaired voiding function and consequent need for intermittent catheterisation may counteract the quality-of-life benefits of improved storage function. Several issues remain uncertain for this unlicensed treatment, and clear insights into long-term consequences are needed before it can be regarded as an established mainstream treatment.
摘要
肉毒杆菌神经毒素在神经源性逼尿肌过度活动症中已取得显著的临床疗效。然而，将其应用于难治性特发性逼尿肌过度活动症的治疗则更具争议性，因为在这种情况下，排尿功能受损的风险以及随之而来的间歇性导尿需求可能会抵消改善储尿功能给生活质量带来的益处。对于这种未经许可的治疗方法，仍有几个问题尚不确定，在其被视为一种成熟的主流治疗方法之前，需要对其长期后果有清晰的认识。
相似文献
1
Intravesical botulinum toxin for lower urinary tract dysfunction.膀胱内注射肉毒杆菌毒素治疗下尿路功能障碍。
F1000 Med Rep. 2010 Jan 27;2:6. doi: 10.3410/M2-6.
2
What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.难治性特发性逼尿肌过度活动患者应了解的A型肉毒杆菌神经毒素注射相关知识。
J Urol. 2009 Apr;181(4):1773-8. doi: 10.1016/j.juro.2008.11.110. Epub 2009 Feb 23.
3
Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.重复膀胱内注射肉毒毒素 A 治疗逼尿肌过度活动的停药率和注射间隔。
Int J Urol. 2014 Feb;21(2):175-8. doi: 10.1111/iju.12205. Epub 2013 Jul 2.
4
Intravesical injection of botulinum toxin for the treatment of overactive bladder.膀胱内注射肉毒杆菌毒素治疗膀胱过度活动症。
Curr Opin Obstet Gynecol. 2005 Oct;17(5):512-8. doi: 10.1097/01.gco.0000180659.09320.3e.
5
Botulinum toxin injection for lower urinary tract dysfunction.肉毒毒素注射治疗下尿路功能障碍。
Int J Urol. 2013 Jan;20(1):40-55. doi: 10.1111/j.1442-2042.2012.03035.x. Epub 2012 May 9.
6
Botulinum toxin-A for the treatment of overactive bladder: UK contributions.用于治疗膀胱过度活动症的A型肉毒杆菌毒素：英国的贡献。
J Clin Urol. 2013 Mar;6(2):77-83. doi: 10.1177/2051415812473096.
7
Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.膀胱内注射树脂毒素与A型肉毒杆菌毒素治疗神经源性逼尿肌过度活动：一项前瞻性随机研究。
J Urol. 2004 Jul;172(1):240-3. doi: 10.1097/01.ju.0000132152.53532.5d.
8
Botulinum toxin treatment for bladder dysfunction.肉毒杆菌毒素治疗膀胱功能障碍。
Int J Urol. 2013 Oct;20(10):956-62. doi: 10.1111/iju.12188. Epub 2013 May 2.
9
New therapeutic options for refractory neurogenic detrusor overactivity.难治性神经源性逼尿肌过度活动的新治疗选择。
Minerva Urol Nefrol. 2004 Mar;56(1):79-87.
10
Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.A型肉毒杆菌神经毒素治疗难治性特发性逼尿肌过度活动症患者的前景与局限性
BJU Int. 2008 Jul 25;102 Suppl 1:7-10. doi: 10.1111/j.1464-410X.2008.07827.x.
本文引用的文献
1
Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder.特发性膀胱过度活动症患者膀胱逼尿肌内注射A型肉毒杆菌毒素反应的预测因素
Adv Urol. 2009;2009:328364. doi: 10.1155/2009/328364. Epub 2009 Sep 8.
2
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.A型肉毒杆菌毒素治疗帕金森病和多系统萎缩患者的膀胱过度活动症及逼尿肌过度活动
J Urol. 2009 Oct;182(4):1453-7. doi: 10.1016/j.juro.2009.06.023. Epub 2009 Aug 15.
3
Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study.肉毒杆菌A毒素/二甲基亚砜膀胱灌注治疗难治性特发性逼尿肌过度活动症女性：一项1/2期研究
Mayo Clin Proc. 2009 Aug;84(8):702-6. doi: 10.4065/84.8.702.
4
Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.重复膀胱逼尿肌内注射A型肉毒杆菌神经毒素对神经源性膀胱功能障碍患者逼尿肌功能的长期影响。
BJU Int. 2009 Nov;104(9):1246-50. doi: 10.1111/j.1464-410X.2009.08600.x. Epub 2009 Apr 4.
5
Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder.一项关于A型肉毒杆菌毒素治疗难治性膀胱过度活动症的随机、双盲、安慰剂对照试验的结果
J Urol. 2009 Jun;181(6):2608-15. doi: 10.1016/j.juro.2009.01.117. Epub 2009 Apr 16.
6
A UK consensus on the management of the bladder in multiple sclerosis.英国关于多发性硬化症膀胱管理的共识。
J Neurol Neurosurg Psychiatry. 2009 May;80(5):470-7. doi: 10.1136/jnnp.2008.159178.
7
Effects of purified newly developed botulinum neurotoxin type A in rat prostate.新研发的纯化A型肉毒杆菌神经毒素对大鼠前列腺的影响。
Urology. 2009 Aug;74(2):436-9. doi: 10.1016/j.urology.2009.01.047. Epub 2009 Apr 15.
8
Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units.肉毒杆菌毒素A治疗特发性膀胱过度活动症剂量探索性研究的初步结果：100单位与150单位对比
Neurourol Urodyn. 2009;28(3):205-8. doi: 10.1002/nau.20611.
9
Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?对接受A型肉毒杆菌毒素治疗的膀胱过度活动症患者的尿动力学和逼尿肌收缩性变量进行评估：膀胱排空不全是否可预测？
BJU Int. 2009 Mar;103(5):630-4. doi: 10.1111/j.1464-410X.2008.08076.x. Epub 2008 Oct 16.
10
Botulinum toxin treatment for overactive bladder: risk of urinary retention.肉毒杆菌毒素治疗膀胱过度活动症：尿潴留风险
Curr Urol Rep. 2008 Nov;9(6):445-51. doi: 10.1007/s11934-008-0077-1.
Zotero 插件